Rituxan deaths reported to FDA

The deaths of two women being treated with Genentech's Rituxan (rituximab) for systemic lupus erythematosus have been reported to the FDA. The agency is working with the company to obtain additional info and to strengthen the warnings in the product labeling.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions